Payment overview · 2025
General Payments
$130.13
6 reported records · 6 companies
Healthcare provider profile · identity verified
Dennis J Schank, MD
Allopathic & Osteopathic Physicians|Family Medicine · BOYERTOWN, PA · NPI 1659346344
Verified facts
What the public records show
CMS Open Payments records show Dennis J Schank, MD received $130.13 in general payments during 2025 across 6 reported records.
Insulet Corporation accounted for 22.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Insulet Corporation | Unresolved — no canonical attribution shown | $28.76 | 22.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $28.27 | 21.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.19 | 17.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.31 | 14.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.44 | 13.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14.16 | 10.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $130.13 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $28.76 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $28.27 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $28.27 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $22.19 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.31 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $14.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
64 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Simvastatin | Simvastatin | 580 | 135 |
| Atorvastatin Calcium | Atorvastatin Calcium | 548 | 140 |
| Amlodipine Besylate | Amlodipine Besylate | 447 | 112 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 441 | 108 |
| Levothyroxine Sodium | Levothyroxine Sodium | 412 | 97 |
| Lisinopril | Lisinopril | 398 | 101 |
| Metformin Hcl | Metformin Hcl | 290 | 66 |
| Omeprazole | Omeprazole | 266 | 61 |
| Furosemide | Furosemide | 244 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 240 | 60 |
| Eliquis | Apixaban | 238 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 231 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 220 | 53 |
| Alprazolam | Alprazolam | 178 | 33 |
| Losartan Potassium | Losartan Potassium | 176 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 169 | 44 |
| Gabapentin | Gabapentin | 140 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 138 | 39 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 131 | 31 |
| Valsartan | Valsartan | 131 | 29 |
| Sertraline Hcl | Sertraline Hcl | 114 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 109 | 28 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 105 | 23 |
| Allopurinol | Allopurinol | 103 | 28 |
| Paroxetine Hcl | Paroxetine Hcl | 103 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 99 | 22 |
| Enalapril Maleate | Enalapril Maleate | 99 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 96 | 22 |
| Warfarin Sodium | Warfarin Sodium | 92 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 79 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 74 | 16 |
| Meloxicam | Meloxicam | 73 | 24 |
| Clonazepam | Clonazepam | 72 | 12 |
| Tramadol Hcl | Tramadol Hcl | 72 | 18 |
| Carvedilol | Carvedilol | 70 | 20 |
| Finasteride | Finasteride | 68 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 65 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 64 | 12 |
| Januvia | Sitagliptin Phosphate | 64 | 17 |
| Synthroid | Levothyroxine Sodium | 64 | 17 |
| Farxiga | Dapagliflozin Propanediol | 63 | 13 |
| Lorazepam | Lorazepam | 60 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 58 | 29 |
| Potassium Chloride | Potassium Chloride | 58 | 15 |
| Jardiance | Empagliflozin | 57 | suppressed |
| Spironolactone | Spironolactone | 57 | 14 |
| Montelukast Sodium | Montelukast Sodium | 55 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 53 | suppressed |
| Nabumetone | Nabumetone | 53 | suppressed |
| Famotidine | Famotidine | 52 | 19 |
| Atenolol | Atenolol | 51 | 13 |
| Ezetimibe | Ezetimibe | 50 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 49 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 48 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 44 | 15 |
| Meclizine Hcl | Meclizine Hcl | 44 | 21 |
| Xarelto | Rivaroxaban | 44 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 41 | 13 |
| Glimepiride | Glimepiride | 39 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 38 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 37 | suppressed |
| Celecoxib | Celecoxib | 36 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 35 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Amoxicillin | Amoxicillin | 32 | 16 |
| Tradjenta | Linagliptin | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 29 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Klor-Con M20 | Potassium Chloride | 27 | suppressed |
| Nystatin | Nystatin | 27 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Prednisone | Prednisone | 24 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Humalog | Insulin Lispro | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Cefdinir | Cefdinir | 15 | 15 |
| Cephalexin | Cephalexin | 15 | 14 |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Azithromycin | Azithromycin | 13 | 12 |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Ramelteon | Ramelteon | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Lyumjev | Insulin Lispro-Aabc | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $130.13 · 6 records | Insulet Corporation | Dexcom G6 Transmitter, FREESTYLE LIBRE, Omnipod, Ozempic, Rybelsus, SHINGRIX, UBRELVY | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error